ESMO 2024 | ctDNA clearance linked to improved outcomes in MIBC neoadjuvant therapy: results from VOLGA study
Alexandra Drakaki, MD, PhD, University of California Los Angeles, Los Angeles, CA, discusses an exploratory analysis of plasma circulating tumor DNA (ctDNA) from the Phase III VOLGA (NCT04960709) safety run-in (SRI) cohort. This study assessed ctDNA dynamics in cisplatin-ineligible patients with muscle-invasive bladder cancer (MIBC) undergoing neoadjuvant durvalumab, tremelimumab, and enfortumab vedotin therapy before radical cystectomy. ctDNA clearance during treatment was associated with improved pathologic response and event-free survival (EFS). These promising results suggest ctDNA clearance as a potential surrogate for treatment efficacy, warranting further investigation in the ongoing VOLGA study. This interview took place at the European Society for Medical Oncology (ESMO) 2024 Congress in Barcelona, Spain.
These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.
